JPMorgan Chase & Co. Issues Pessimistic Forecast for Haemonetics (NYSE:HAE) Stock Price

by · The Cerbat Gem

Haemonetics (NYSE:HAE – Get Free Report) had its target price reduced by stock analysts at JPMorgan Chase & Co. from $74.00 to $62.00 in a research note issued to investors on Friday,Benzinga reports. The brokerage presently has a “neutral” rating on the medical instruments supplier’s stock. JPMorgan Chase & Co.‘s target price indicates a potential upside of 12.60% from the stock’s previous close.

Several other research analysts also recently weighed in on HAE. Citigroup lowered their target price on Haemonetics from $75.00 to $70.00 and set a “neutral” rating on the stock in a research note on Wednesday, March 11th. Barrington Research set a $94.00 price target on Haemonetics in a report on Friday, February 6th. Wall Street Zen upgraded shares of Haemonetics from a “hold” rating to a “buy” rating in a research report on Saturday, January 10th. BTIG Research reissued a “buy” rating and issued a $88.00 price objective on shares of Haemonetics in a research note on Friday, February 6th. Finally, Mizuho cut their price objective on shares of Haemonetics from $80.00 to $70.00 and set an “outperform” rating for the company in a research report on Monday, April 13th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat, Haemonetics currently has an average rating of “Moderate Buy” and a consensus price target of $79.89.

Check Out Our Latest Report on Haemonetics

Haemonetics Price Performance

Shares of NYSE:HAE opened at $55.06 on Friday. Haemonetics has a one year low of $47.31 and a one year high of $87.32. The stock has a market capitalization of $2.56 billion, a price-to-earnings ratio of 27.26, a PEG ratio of 1.08 and a beta of 0.53. The company has a 50-day simple moving average of $59.53 and a 200-day simple moving average of $66.68. The company has a debt-to-equity ratio of 1.53, a quick ratio of 1.15 and a current ratio of 2.95.

Haemonetics (NYSE:HAE – Get Free Report) last released its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $1.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.28 by $0.01. The firm had revenue of $346.35 million for the quarter, compared to analyst estimates of $336.83 million. Haemonetics had a return on equity of 27.30% and a net margin of 7.29%.The business’s revenue was up 4.8% on a year-over-year basis. During the same quarter last year, the company posted $1.24 earnings per share. Haemonetics has set its FY 2027 guidance at 5.258-5.307 EPS. On average, analysts predict that Haemonetics will post 5.28 EPS for the current year.

Institutional Trading of Haemonetics

Several hedge funds have recently modified their holdings of HAE. Dimensional Fund Advisors LP grew its holdings in Haemonetics by 21.3% during the first quarter. Dimensional Fund Advisors LP now owns 1,326,057 shares of the medical instruments supplier’s stock worth $74,731,000 after acquiring an additional 233,119 shares during the period. Heartland Advisors Inc. lifted its holdings in Haemonetics by 13.3% in the first quarter. Heartland Advisors Inc. now owns 85,000 shares of the medical instruments supplier’s stock valued at $4,791,000 after acquiring an additional 10,000 shares during the period. Jennison Associates LLC boosted its position in shares of Haemonetics by 86.2% during the 1st quarter. Jennison Associates LLC now owns 22,536 shares of the medical instruments supplier’s stock worth $1,270,000 after purchasing an additional 10,433 shares in the last quarter. Aurora Investment Counsel purchased a new stake in shares of Haemonetics during the 1st quarter worth $1,217,000. Finally, Principal Financial Group Inc. grew its stake in shares of Haemonetics by 25.4% during the 1st quarter. Principal Financial Group Inc. now owns 205,456 shares of the medical instruments supplier’s stock worth $11,580,000 after purchasing an additional 41,677 shares during the period. 99.67% of the stock is owned by institutional investors and hedge funds.

Key Headlines Impacting Haemonetics

Here are the key news stories impacting Haemonetics this week:

Haemonetics Company Profile

(Get Free Report)

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.

Recommended Stories